alfa amilase diabetes - Amylase inhibitors play a defensive role geen diabetes wel lage bloedsuiker in diabetic patients Ali et al 2006Diabetes mellitus is a metabolic disruption with multiple aetiologies specifically marked by chronic hyperglycaemia along with disturbance of carbohydrate protein and fat metabolism caused by flaws in insulin secretion or an action of insulin WHO 1999The World Health Organization WHO proposed that the global Natural Inhibitors of Mammalian αAmylases as Promising Drugs for the Background αamylase and αglucosidase digest the carbohydrates and increase the postprandial glucose level in diabetic patients Inhibiting the activity of these two enzymes can control postprandial hyperglycemia and reduce the risk of developing diabetes Bitter gourd or balsam pear is one of the important medicinal plants used for controlling postprandial hyperglycemia in diabetes αAmylase Inhibitors Performance in the Control of Diabetes Mellitus AlphaAmylase and AlphaGlucosidase Enzyme Inhibition and Antioxidant Inhibition mechanism of alphaamylase a diabetes target by a Alphaamylase as molecular target for treatment of diabetes PubMed Alphaamylase as molecular target for treatment of diabetes mellitus A comprehensive review Navjot Kaur Navjot Kaur School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India Search for more papers by this author Vanktesh Kumar Vanktesh Kumar Alphaamylase inhibition can treat diabetes mellitus ResearchGate Inhibition mechanism of alphaamylase a diabetes target by a Keywords diabetes alphaamylase G latifolium phytochemicals pregnanes molecular docking molecular dynamics simulations Graphical Abstract Introduction Diabetes mellitus DM a metabolic disease syndrome is ranked among the persistent and most challenging public health burdens worldwide According to the International Diabetes Federation the global diabetes prevalence in 2079yearolds in 2021 was estimated to be 105 5366 diabetes melitus menurut who 2013 million people and is expected to rise to 122 7832 million in 2045 The number of diabetes cases is growing at an increasing speed Type 2 diabetes mellitus T2DM is characterized by elevated blood glucose levels and can lead to serious complications such as nephropathy neuropathy retinopathy and cardiovascular disease 12 T2DM remains one of the most common health issues and accounts for 90 of the cases of diabetes with a mortality incidence of 49 million people Alphaamylase as molecular target for treatment of diabetes mellitus A The inhibition of alphaglucosidase and alphaamylase enzymes involved in the digestion of carbohydrates can significantly reduce the postprandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patien Alphaamylase is widely exploited as a drug target for preventing postprandial hyperglycemia in diabetes and other metabolic diseases Inhibition of this enzyme by plantderived pregnanes is not fully understood Herein we used iin vitroi iin silicoi and iin vivoi studies to provid Natural products as alphaamylase and alphaglucosidase inhibitors and In vitro and in vivo αamylase and αglucosidase inhibiting activities Alphaamylase is responsible for postprandial glucose levels therefore different plant extracts with alphaamylase inhibitory activity are being investigated that might decrease postprandial alphaAmylases benzofuran voglibose Acarbose The alpha αamylase is a calcium metalloenzyme that aids digestion by breaking down polysaccharide molecules into smaller ones such as glucose and maltose In addition the enzyme causes postprandial hyperglycaemia and blood glucose levels to rise αAmylase is diabetes range before and after food a wellknown therapeutic target
finger pricker for diabetes
american diabetes guidelines 2019 pdf
